Please ensure Javascript is enabled for purposes of website accessibility

UnitedHealth Group Validates a Self-Administered COVID-19 Test

By Cory Renauer - Mar 26, 2020 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Results from a 500-patient study show that coronavirus tests that use self-administered swabs are just as accurate as those using samples collected by medical professionals.

UnitedHealth Group (UNH 0.29%) on Wednesday announced results of a 500-patient study that it hopes will lead the Food and Drug Administration to soften its generally negative stance on self-administered testing. The study found tests conducted using patient-collected samples accurately detected COVID-19 in more than 90% of positive patients, which is just as good as swabs taken by healthcare professionals.

Reducing strain on the system 

Currently, testing for COVID-19 requires a trained clinician to collect a sample from deep in the nasal cavity, which means they need to dip into a dwindling supply of personal protective equipment with each patient.

Doctor swabbing a sample.

Image source: Getty Images.

The method UnitedHealth Group tested works with samples collected from the middle of the nose that patients can collect on their own, at home.

Looking ahead

Simple patient-administered testing would go a long way to help public health officials decide which areas need to remain locked down and which can relax restrictions. But inaccurate (or fraudulent) tests could flood overtaxed hospitals with healthy people who shouldn't be there or prevent sick patients from seeking the help they need.

It's difficult to guess how the FDA will react to UnitedHealth's clinical trial results. A few years ago, the agency discussed the potential of at-home and over-the-counter testing for HIV, strep throat, and the flu. At the time, the agency concluded that it was still better to have professionals collect specimens, but that was before the COVID-19 pandemic threatened to overwhelm the nation's hospitals and deplete their supplies of protective gear.  As of March 20, however, the FDA was still officially holding the line against self-administered coronavirus tests.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$536.60 (0.29%) $1.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.